Cargando…
Anti-Angiogenic Property of Free Human Oligosaccharides
Angiogenesis, a fundamental process in human physiology and pathology, has attracted considerable attention owing to its potential as a therapeutic strategy. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are deemed major mediators of angiogenesis. To date, inhibition of the VEGF...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224327/ https://www.ncbi.nlm.nih.gov/pubmed/34064180 http://dx.doi.org/10.3390/biom11060775 |
_version_ | 1783711864947998720 |
---|---|
author | Bae, Boram Kim, Haeun Park, Hyerin Koh, Young Jun Bae, Sung-Jin Ha, Ki-Tae |
author_facet | Bae, Boram Kim, Haeun Park, Hyerin Koh, Young Jun Bae, Sung-Jin Ha, Ki-Tae |
author_sort | Bae, Boram |
collection | PubMed |
description | Angiogenesis, a fundamental process in human physiology and pathology, has attracted considerable attention owing to its potential as a therapeutic strategy. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are deemed major mediators of angiogenesis. To date, inhibition of the VEGF-A/VEGFR-2 axis has been an effective strategy employed in the development of anticancer drugs. However, some limitations, such as low efficacy and side effects, need to be addressed. Several drug candidates have been discovered, including small molecule compounds, recombinant proteins, and oligosaccharides. In this review, we focus on human oligosaccharides as modulators of angiogenesis. In particular, sialylated human milk oligosaccharides (HMOs) play a significant role in the inhibition of VEGFR-2-mediated angiogenesis. We discuss the structural features concerning the interaction between sialylated HMOs and VEGFR-2 as a molecular mechanism of anti-angiogenesis modulation and its effectiveness in vivo experiments. In the current state, extensive clinical trials are required to develop a novel VEGFR-2 inhibitor from sialylated HMOs. |
format | Online Article Text |
id | pubmed-8224327 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82243272021-06-25 Anti-Angiogenic Property of Free Human Oligosaccharides Bae, Boram Kim, Haeun Park, Hyerin Koh, Young Jun Bae, Sung-Jin Ha, Ki-Tae Biomolecules Review Angiogenesis, a fundamental process in human physiology and pathology, has attracted considerable attention owing to its potential as a therapeutic strategy. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are deemed major mediators of angiogenesis. To date, inhibition of the VEGF-A/VEGFR-2 axis has been an effective strategy employed in the development of anticancer drugs. However, some limitations, such as low efficacy and side effects, need to be addressed. Several drug candidates have been discovered, including small molecule compounds, recombinant proteins, and oligosaccharides. In this review, we focus on human oligosaccharides as modulators of angiogenesis. In particular, sialylated human milk oligosaccharides (HMOs) play a significant role in the inhibition of VEGFR-2-mediated angiogenesis. We discuss the structural features concerning the interaction between sialylated HMOs and VEGFR-2 as a molecular mechanism of anti-angiogenesis modulation and its effectiveness in vivo experiments. In the current state, extensive clinical trials are required to develop a novel VEGFR-2 inhibitor from sialylated HMOs. MDPI 2021-05-21 /pmc/articles/PMC8224327/ /pubmed/34064180 http://dx.doi.org/10.3390/biom11060775 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bae, Boram Kim, Haeun Park, Hyerin Koh, Young Jun Bae, Sung-Jin Ha, Ki-Tae Anti-Angiogenic Property of Free Human Oligosaccharides |
title | Anti-Angiogenic Property of Free Human Oligosaccharides |
title_full | Anti-Angiogenic Property of Free Human Oligosaccharides |
title_fullStr | Anti-Angiogenic Property of Free Human Oligosaccharides |
title_full_unstemmed | Anti-Angiogenic Property of Free Human Oligosaccharides |
title_short | Anti-Angiogenic Property of Free Human Oligosaccharides |
title_sort | anti-angiogenic property of free human oligosaccharides |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224327/ https://www.ncbi.nlm.nih.gov/pubmed/34064180 http://dx.doi.org/10.3390/biom11060775 |
work_keys_str_mv | AT baeboram antiangiogenicpropertyoffreehumanoligosaccharides AT kimhaeun antiangiogenicpropertyoffreehumanoligosaccharides AT parkhyerin antiangiogenicpropertyoffreehumanoligosaccharides AT kohyoungjun antiangiogenicpropertyoffreehumanoligosaccharides AT baesungjin antiangiogenicpropertyoffreehumanoligosaccharides AT hakitae antiangiogenicpropertyoffreehumanoligosaccharides |